G1 is developing novel therapeutics for the treatment of cancer. Our two clinical-stage candidates – trilaciclib and G1T38 – are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 have the potential to treat most types of cancer, and were designed to be combined – and enhance – the anti-tumor activity of current therapies. We are also advancing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer.G1 was founded by Ned Sharpless, MD, Director of the UNC Lineberger Comprehensive Cancer Center at UNC-Chapel Hill, and Kwok-Kin Wong, MD, PhD, Chief of Hematology and Medical Oncology at the Perlmutter Cancer Center, NYU Langone Medical Center. G1’s internal team and scientific/clinical advisors have a deep understanding of the biology of CDK4/6, and extensive drug discovery and clinical oncology development experience.